Bio-Rad Laboratories (BIO) and (BIO.B) and the wholly owned subsidiary of Myriad Genetics (MYGN), Myriad RBM, have joined forces to develop and distribute immunoassay kits.
As part of the agreement, Myriad RBM will provide Bio-Rad with distribution rights for research purposes, to the catalog of quantitative multiplexed immunoassays present to run on the Bio-Plex 200,Bio-Plex 3D, and Bio-PlexMAGPIX instruments.
Bio-Rad Life Science Group vice president and group manager Brad Crutchfield said the companies are able to provide hundreds of biomarkers for both human and non-human panels to their Bio-Plex multiplex immunoassay system menu.
"Moving forward, Myriad RBM and Bio-Rad will collaborate to design new products to meet the evolving requirements of our customers," Crutchfield added.
Myriad RBM president Craig Benson said the agreement combines Myriad RBM's multiplexed immunoassays with Bio-Rad's global commercial distribution capabilities.
"Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care," Benson added.
Myriad RBM assays address the needs of researchers for multiplex testing of samples with very low volumes while studying toxicology, oncology, immunology and cardiovascular and other diseases.
